Basilea receives BARDA funding

Basilea Pharmaceutica>>> announced that the United States — Biomedical Advanced Research and Development Authority>>> (BARDA), a part of the United States — United States Department of Health and Human Services>>>, awarded it USD 13.3 million. This funding is designated for the continued development of Basilea Pharmaceutica>>>'s novel oral antibiotic, ceftibuten-ledaborbactam etzadroxil, which is intended for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. This latest tranche brings the total committed by BARDA to USD 25 million, with a potential for up to USD 133 million in additional non-dilutive funding. David Veitch>>>, CEO of Basilea Pharmaceutica>>>, emphasized that this funding will help advance the antibiotic, including preparations for its clinical phase 3 program, to address the critical unmet need for oral treatments against multidrug-resistant Gram-negative bacteria. The antibiotic has also received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the United States — Food and Drug Administration>>>.